| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | STMN1; C1orf215; LAP18; OP18; Stathmin; Leukemia-associated phosphoprotein p18; Metablastin; Oncoprotein 18; Op18; Phosphoprotein p19; pp19; Prosolin; Protein Pr22; pp17 |
| Entrez GeneID | 3925 |
| WB Predicted band size | Calculated MW: 17 kDa; Observed MW: 17 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Stathmin 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Stathmin 1抗体的3篇参考文献及其摘要内容(模拟虚构，仅供参考格式)：
1. **文献名称**: *Stathmin 1 overexpression in breast cancer: a novel prognostic marker and therapeutic target*
**作者**: Lee, S. et al.
**摘要**: 该研究利用Stathmin 1特异性抗体通过免疫组化分析乳腺癌组织，发现Stathmin 1高表达与肿瘤侵袭性和不良预后相关，提示其作为潜在治疗靶点的价值。
2. **文献名称**: *Monoclonal antibody characterization of Stathmin 1 in neurodegenerative disorders*
**作者**: Zhang, Y. et al.
**摘要**: 通过Western blot和免疫荧光验证了Stathmin 1抗体在阿尔茨海默病模型中的特异性，发现Stathmin 1在神经元轴突退化中的动态变化，为神经疾病机制研究提供工具。
3. **文献名称**: *Validation of anti-Stathmin 1 antibodies for differential diagnosis of lymphoid malignancies*
**作者**: Rossi, M. et al.
**摘要**: 研究评估了多种商用Stathmin 1抗体的灵敏度和特异性，证实其在流式细胞术和免疫印染中可有效区分淋巴瘤亚型，支持其在临床诊断中的应用。
4. **文献名称**: *Stathmin 1 regulates cell cycle progression via microtubule dynamics in ovarian cancer*
**作者**: Gupta, R. et al.
**摘要**: 通过siRNA敲低和Stathmin 1抗体共定位实验，揭示其通过微管稳定性调控卵巢癌细胞有丝分裂的机制，为靶向治疗提供依据。
(注：以上文献为示例格式，实际引用需根据具体文献调整。)
Stathmin 1. also known as oncoprotein 18 (OP18), is a cytosolic phosphoprotein that plays a critical role in regulating microtubule dynamics. It functions by binding to tubulin heterodimers or microtubules, promoting depolymerization or preventing polymerization, thereby influencing cell division, intracellular transport, and signal transduction. Its activity is tightly regulated by phosphorylation, particularly during the cell cycle, where it coordinates mitotic spindle formation. Overexpression of Stathmin 1 is associated with cellular proliferation, malignant transformation, and poor prognosis in various cancers, including breast, ovarian, and prostate cancers, making it a potential therapeutic target and biomarker.
Antibodies targeting Stathmin 1 are widely used in research to investigate its expression, localization, and functional roles. These antibodies enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validation often includes knockdown experiments or comparison with Stathmin 1-deficient cell lines to confirm specificity. In cancer studies, such antibodies help assess Stathmin 1’s correlation with tumor aggressiveness, metastasis, or drug resistance. Additionally, they are employed in studying neurological disorders, as Stathmin 1 is implicated in neuronal development and synaptic plasticity. Researchers prioritize antibodies with high affinity and minimal cross-reactivity to related proteins (e.g., other stathmin family members) to ensure accurate data interpretation. Commercial availability from multiple suppliers has facilitated its adoption in both basic and translational research contexts.
×
